CA-PLUS
9.5.2022 14:02:08 CEST | Business Wire | Press release
Plus, a global provider of self-driving truck technology, announced today that it has selected Velociti, a global leader in fleet technology solutions, as the deployment and maintenance partner for the national Plus Build program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510005059/en/
The Plus Build program takes less than a day to turn new and existing Class 8 freight trucks into semi-autonomous trucks by equipping them with state-of-the-art lidar, radar, and camera sensors and Plus’s proprietary autonomous driving software. The result is PlusDrive, the industry’s first commercially available autonomous trucking solution. PlusDrive improves safety, enhances driver comfort, and saves at least 10% in fuel costs. Installation is performed at locations most convenient to customers, in or near major transportation hubs across the U.S. Maintenance services are available nationwide by utilizing mobile resources to meet customers where they are.
Shawn Kerrigan, COO and Co-founder of Plus, said: “Plus Build helps companies unlock the benefits of autonomous driving technology today by quickly modernizing trucks to improve their safety and uptime. Velociti’s unmatched technology installation and service network will help us get PlusDrive into the hands of more truck drivers across the country to make their jobs safer, easier, and better.”
Through the Plus Build program and partnership with Velociti, Plus is now deploying PlusDrive nationwide. Some of the world’s largest fleets and truck manufacturers are already participating in Plus Build and are operating PlusDrive-enabled trucks on the road today. In addition to Velociti’s technology installation services, Plus is implementing Velociti’s VeloCare solution, a flagship proactive system-health monitoring program including remote and mobile services to maximize technology uptime.
“Partnering with Plus to provide our services as an important part of the PlusDrive solution leverages Velociti’s decades of experience deploying and maintaining innovative fleet technologies. We are excited to enter into this strategic partnership to help PlusDrive customers realize the benefits this transformational technology brings to their businesses and to the transportation industry,” said Ryan Powell, Senior Vice President at Velociti.
Supervised by a truck operator, PlusDrive can autonomously handle the following in normal traffic conditions on a highway:
- Lane centering
- Driver initiated lane change
- Traffic jam assist
- Predictive fuel optimization
- Adaptive cruise control (down to zero)
- Lane merging
- Driver attentiveness detection
- Operational Design Domain (ODD) checker
- Self-calibration
- Over-the-air updates
For more information on the Plus Build program or PlusDrive, please contact sales@plus.ai .
About Plus
Plus is a global leader in the autonomous trucking revolution, with award-winning high-performance full-stack driverless technology. Named by Fast Company as one of the World’s Most Innovative Companies of 2022, Plus is the only autonomous driving company with customers operating its product on the road today. Working with one of the largest companies in the U.S., vehicle manufacturers and others, Plus is making long-haul trucking safer, more fuel efficient, more sustainable, and more comfortable for the drivers. Plus has received a number of industry awards and distinctions for its transformative technology and business momentum from Fast Company , Insider , Consumer Electronics Show , AUVSI , and others.
For more information, please visit www.plus.ai or follow us on LinkedIn or YouTube .
About Velociti
Velociti, a global provider of enterprise technology solutions for more than 25 years, helps meet complex business needs by optimizing technology investments, lowering costs, and improving employee and customer experience. Its innovative design, rapid installation and deployment, and proactive support services for a broad range of transportation and networking technologies are provided by a highly experienced team of engineers, project managers, certified technicians and customer success representatives. Velociti serves enterprises in transportation and logistics, construction, retail, food service, manufacturing, distribution, government, and hospitality including many Fortune 500 companies.
For more information visit http://www.velociti.com or call toll free (855)-233-7210.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom